AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25596660 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiotherapy (three cycles of cisplatin 100 mg/m(2))
Number of subjects: 150
Study 25596660 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab plus chemoradiotherapy (three cycles of intravenous panitumumab 9.0 mg/kg every 3 weeks plus cisplatin 75 mg/m(2))
Number of subjects: 150
Study 25596660 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiotherapy
Number of subjects: 150
Study 25596660 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab plus chemoradiotherapy
Number of subjects: 150
Study 23131530 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 1 mg/kg/day as morning dose
Number of subjects: 100
Study 23131530 — intervention group
Group type: COMPARATOR
Intervention: General preventive measures for UTI
Number of subjects: 100
Study 22379918 — intervention group
Group type: EXPERIMENTAL
Intervention: FFP 5423+417 ml and crystalloids 11048+458 ml (1:2 ratio)
Number of subjects: 66
Study 22379918 — intervention group
Group type: EXPERIMENTAL
Intervention: FFP 6882+943 ml and crystalloids 6690+882 ml (1:1 ratio)
Number of subjects: 66
Study 22379918 — intervention group
Group type: EXPERIMENTAL
Intervention: FFP 7532+1196 ml and crystalloids 3720+629 ml (2:1 ratio)
Number of subjects: 66
Study 19364893 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health technology with blood glucose sensor and Bluetooth transmission
Number of subjects: 137
Study 19364893 — intervention group
Group type: COMPARATOR
Intervention: Usual care without telemonitoring
Number of subjects: 137
Study 16356651 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 13
Study 16356651 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA)
Number of subjects: 13
Study 16356651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 15058858 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior items of varying difficulty (easy vs. difficult)
Number of subjects: 0
Study 15058858 — intervention group
Group type: COMPARATOR
Intervention: Intermediate-difficulty items following easy items
Number of subjects: 0
Study 11124005 — intervention group
Group type: EXPERIMENTAL
Intervention: failure feedback
Number of subjects: 54
Study 11124005 — intervention group
Group type: EXPERIMENTAL
Intervention: success feedback
Number of subjects: 54
Study 11124005 — intervention group
Group type: COMPARATOR
Intervention: neutral control task
Number of subjects: 54
Study 9050390 — intervention group
Group type: EXPERIMENTAL
Intervention: Trick task
Number of subjects: 68
Study 9050390 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced information processing task
Number of subjects: 68
Study 9050390 — intervention group
Group type: COMPARATOR
Intervention: Standard appearance-reality task
Number of subjects: 68
Study 7514771 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine or Heroin (specific dosage not mentioned)
Number of subjects: 168
Study 7514771 — intervention group
Group type: EXPERIMENTAL
Intervention: Definite nociceptive pain
Number of subjects: 168
Study 3315824 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic intravariceal sclerotherapy
Number of subjects: 66
Study 3315824 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous transhepatic obliteration (PTO)
Number of subjects: 66
Study 30928252 — intervention group
Group type: EXPERIMENTAL
Intervention: ICRS followed by CXL (concurrent)
Number of subjects: 198
Study 30928252 — intervention group
Group type: COMPARATOR
Intervention: ICRS followed by CXL 3 months later (sequential)
Number of subjects: 198
Study 28485659 — intervention group
Group type: EXPERIMENTAL
Intervention: self‐generation learning program (self‐GEN trial)
Number of subjects: 35
Study 28485659 — intervention group
Group type: COMPARATOR
Intervention: placebo control
Number of subjects: 35
Study 27798042 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month lifestyle intervention preceding infertility treatment
Number of subjects: 577
Study 27798042 — intervention group
Group type: COMPARATOR
Intervention: Prompt infertility treatment
Number of subjects: 577
Study 27798042 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month lifestyle intervention
Number of subjects: 577
Study 25373067 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubber mannequin IV training arms
Number of subjects: 260
Study 25373067 — intervention group
Group type: COMPARATOR
Intervention: Students performing the procedure on each other
Number of subjects: 260
Study 22270749 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic only
Number of subjects: 60
Study 22270749 — intervention group
Group type: COMPARATOR
Intervention: Local anesthetic mixed with non-particulate betamethasone
Number of subjects: 60
Study 20817598 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin 6mg (DXP)
Number of subjects: 565
Study 17982321 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba (EGb 761, 300 mg/day)
Number of subjects: 55
Study 17982321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 14768768 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental audiotape incorporating components of protection motivation theory
Number of subjects: 46
Study 14768768 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard asthma management booklet
Number of subjects: 46
Study 14768768 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group (audiotape and booklet)
Number of subjects: 46
Study 14768768 — intervention group
Group type: COMPARATOR
Intervention: No educational materials (control group)
Number of subjects: 46
Study 14768768 — intervention group
Group type: COMPARATOR
Intervention: Control group vs. Booklet group
Number of subjects: 46
Study 14768768 — intervention group
Group type: COMPARATOR
Intervention: Control group vs. Combined group
Number of subjects: 46
Study 11073288 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg oral dose of imiquimod after fasting
Number of subjects: 16
Study 11073288 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg oral dose of imiquimod after a standardized, high fat meal
Number of subjects: 16
Study 11073288 — intervention group
Group type: COMPARATOR
Intervention: 30 mg subcutaneous dose of imiquimod
Number of subjects: 16
Study 9198818 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenazone
Number of subjects: 41
Study 9198818 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylation phenotype
Number of subjects: 41
Study 9198818 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy women)
Number of subjects: 41
Study 1319110 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium-enriched cereal (114 g/d)
Number of subjects: 44
Study 1319110 — intervention group
Group type: COMPARATOR
Intervention: Wheat-bran cereal
Number of subjects: 44
Study 2984980 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasally administered enviroxime
Number of subjects: 0
Study 2984980 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated group)
Number of subjects: 0
Study 3694540 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (LZ) 1.5‐9.0 mg
Number of subjects: 9
Study 3694540 — intervention group
Group type: EXPERIMENTAL
Intervention: Meprobamate (MEP) 600‐3600 mg
Number of subjects: 9
Study 3694540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 30972904 — intervention group
Group type: EXPERIMENTAL
Intervention: Knutson's formula (povidone-iodine and sugar solution)
Number of subjects: 34
Study 30972904 — intervention group
Group type: COMPARATOR
Intervention: Traditional topical drugs
Number of subjects: 34
Study 29095379 — intervention group
Group type: EXPERIMENTAL
Intervention: Patterned Feeding Experience (PFE)
Number of subjects: 7
Study 29095379 — intervention group
Group type: COMPARATOR
Intervention: Usual Feeding Care (UFC)
Number of subjects: 7
Study 25585890 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton therapy at a dose of 54 Gy in 30 fractions
Number of subjects: 20
Study 23683448 — intervention group
Group type: EXPERIMENTAL
Intervention: 5mL.kg(‐1) of 0.9% normal saline 10 minutes before induction
Number of subjects: 69
Study 23683448 — intervention group
Group type: COMPARATOR
Intervention: Control group (received nothing)
Number of subjects: 69
Study 23683448 — intervention group
Group type: COMPARATOR
Intervention: Both groups (saline and control)
Number of subjects: 69
Study 20673739 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer stimulus durations (blocked presentation mode) in Experiment 2
Number of subjects: 0
Study 20673739 — intervention group
Group type: COMPARATOR
Intervention: Randomized stimulus durations in Experiment 1
Number of subjects: 0
Study 20673739 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing stimulus duration (both experiments)
Number of subjects: 0
Study 18781484 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infusion
Number of subjects: 10
Study 18781484 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% glucose infusion
Number of subjects: 10
Study 16505084 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium supplementation (620 mg table salt)
Number of subjects: 413
Study 16505084 — intervention group
Group type: COMPARATOR
Intervention: Placebo (596 mg starch)
Number of subjects: 413
Study 16505084 — intervention group
Group type: COMPARATOR
Intervention: No supplementation
Number of subjects: 413
Study 12740158 — intervention group
Group type: EXPERIMENTAL
Intervention: HPS cream (Crystacide 1%) applied topically twice daily for 8 weeks
Number of subjects: 60
Study 12740158 — intervention group
Group type: COMPARATOR
Intervention: Benzoyl peroxide gel (PanOxyl gel 4%) applied topically twice daily for 8 weeks
Number of subjects: 60
Study 12903500 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral furtulon therapy
Number of subjects: 103
Study 12903500 — intervention group
Group type: COMPARATOR
Intervention: Instillation of mitomycin C
Number of subjects: 103
Study 12903500 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 103
Study 9313274 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 119
Study 9313274 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Number of subjects: 119
Study 9313274 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 119
Study 9313274 — intervention group
Group type: COMPARATOR
Intervention: All three opioids (morphine, hydromorphone, sufentanil)
Number of subjects: 119
Study 7691253 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive weekly chemotherapy (VAPEC-B) alone
Number of subjects: 50
Study 7691253 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive weekly chemotherapy (VAPEC-B) with granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 50
Study 7691253 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy alone or chemotherapy with G-CSF
Number of subjects: 50
Study 3536397 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg ISDN
Number of subjects: 49
Study 3536397 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg ISDN
Number of subjects: 49
Study 3536397 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg ISDN
Number of subjects: 49
Study 3536397 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg ISDN
Number of subjects: 49
Study 3536397 — intervention group
Group type: EXPERIMENTAL
Intervention: ISDN (all doses)
Number of subjects: 49
Study 30318772 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab treatment in patients with FCGR2A H/H genotype (n=165, 28%)
Number of subjects: 592
Study 30318772 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab treatment in patients with FCGR2A R/- genotype (n=427, 72%)
Number of subjects: 592
Study 30318772 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab treatment in patients with FCGR2A H/R genotype
Number of subjects: 592
Study 30318772 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab treatment in patients with FCGR2A H/H + FCGR3A F/F genotype
Number of subjects: 592
Study 30318772 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab treatment
Number of subjects: 592
Study 27873423 — intervention group
Group type: EXPERIMENTAL
Intervention: Smile intervention (performing an easy cognitive task while smiling; n = 11)
Number of subjects: 20
Study 27873423 — intervention group
Group type: COMPARATOR
Intervention: Control group (performing an easy cognitive task without smiling; n = 9)
Number of subjects: 20
Study 27873423 — intervention group
Group type: EXPERIMENTAL
Intervention: Smile intervention
Number of subjects: 20
Study 27873423 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 24114425 — intervention group
Group type: EXPERIMENTAL
Intervention: Mecamylamine 10 mg
Number of subjects: 71
Study 24114425 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline 1 mg
Number of subjects: 71
Study 24114425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 23124047 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP-based lifestyle intervention
Number of subjects: 241
Study 23124047 — intervention group
Group type: COMPARATOR
Intervention: Contact attempted for 2391 patients
Number of subjects: 241
Study 23124047 — intervention group
Group type: COMPARATOR
Intervention: Screening of patients
Number of subjects: 241
Study 23124047 — intervention group
Group type: EXPERIMENTAL
Intervention: All clinic physicians agreed to participate
Number of subjects: 241
Study 20034947 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple dye plus rubbing alcohol (isopropyl alcohol) twice daily
Number of subjects: 90
Study 20034947 — intervention group
Group type: COMPARATOR
Intervention: Triple dye alone (brilliant green, crystal violet, and proflavine hemisulfate)
Number of subjects: 90
Study 18665684 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 136
Study 18665684 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional family therapy (MDFT)
Number of subjects: 136
Study 18665684 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist competence
Number of subjects: 136
Study 16632346 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by craniospinal RT (35 Gy in 21 fractions + boost of 20 Gy in 12 fractions)
Number of subjects: 68
Study 16632346 — intervention group
Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 68
Study 16632346 — intervention group
Group type: EXPERIMENTAL
Intervention: Pineal primary site
Number of subjects: 68
Study 16632346 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pineal primary site
Number of subjects: 68
Study 12752841 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial interventions for caregivers
Number of subjects: 30
Study 11049903 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 453
Study 11049903 — intervention group
Group type: COMPARATOR
Intervention: Thiopental and Isoflurane
Number of subjects: 453
Study 11049903 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 453
Study 8835126 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow's milk challenge
Number of subjects: 100
Study 1424853 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous monitoring with pulse oximetry available at the bedside (group 1)
Number of subjects: 35
Study 1424853 — intervention group
Group type: COMPARATOR
Intervention: Continuous monitoring with pulse oximetry masked at the bedside (group 2)
Number of subjects: 35
Study 1424853 — intervention group
Group type: COMPARATOR
Intervention: Continuous monitoring with pulse oximetry (group 2)
Number of subjects: 35
Study 3906875 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrazinamide (Z) combined with Isoniazid (H) and Rifampicin (R)
Number of subjects: 190
Study 3906875 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethambutol (E) combined with Isoniazid (H) and Rifampicin (R)
Number of subjects: 190
Study 3906875 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin (R) combined with Isoniazid (H)
Number of subjects: 190
Study 3906875 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethambutol (E) combined with Isoniazid (H)
Number of subjects: 190
Study 3906875 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 190
Study 31731527 — intervention group
Group type: EXPERIMENTAL
Intervention: Altilix® supplementation
Number of subjects: 100
Study 29995181 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and motivation instructions in oral health and plaque control
Number of subjects: 38
Study 29995181 — intervention group
Group type: COMPARATOR
Intervention: Dental prophylaxis
Number of subjects: 38
Study 29231293 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at Zusanli (ST 36) and Zhigou (TE 6), 30 min for each treatment, once a day for 5 days.
Number of subjects: 140
Study 29231293 — intervention group
Group type: COMPARATOR
Intervention: Regular treatment including intensive care, gastrointestinal decompression, fasting, blood capacity supplement, acid suppression treatment, internal environment maintenance, infection prevention, inhibition of pancreatic exocrine secretion.
Number of subjects: 140
Study 24351100 — intervention group
Group type: EXPERIMENTAL
Intervention: Low central venous pressure (≤5 mmHg)
Number of subjects: 92
Study 24351100 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute normovolemic hemodilution
Number of subjects: 92
Study 24351100 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluid management
Number of subjects: 92
Study 24351100 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 92
Study 22078660 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation (400mg daily) + Calcium (1200mg) + Vitamin D(3) (1000 IU)
Number of subjects: 40
Study 22078660 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Calcium (1200mg) + Vitamin D(3) (1000 IU)
Number of subjects: 40
Study 19606508 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture group (PC6 and ST36 acupoints)
Number of subjects: 30
Study 19606508 — intervention group
Group type: COMPARATOR
Intervention: Sham group (1 cm away from PC6 and ST36 acupoints)
Number of subjects: 30
Study 19606508 — intervention group
Group type: COMPARATOR
Intervention: Normal group (no acupuncture)
Number of subjects: 30
Study 17257532 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilization in a removable cast
Number of subjects: 62
Study 17257532 — intervention group
Group type: COMPARATOR
Intervention: Nonweightbearing below‐knee cast
Number of subjects: 62
Study 15308515 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (IFX) 3 mg/kg, three i.v. infusions on weeks 0, 2, and 6
Number of subjects: 21
Study 15308515 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone (MP) 1 g, single i.v. infusion
Number of subjects: 21
Study 15308515 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (IFX)
Number of subjects: 21
Study 15308515 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone (MP)
Number of subjects: 21
Study 11468195 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin (0.15 mg/d for 3 days)
Number of subjects: 27
Study 11468195 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 27
Study 9543975 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel dressing A
Number of subjects: 50
Study 9543975 — intervention group
Group type: COMPARATOR
Intervention: Hydrogel dressing B
Number of subjects: 50
Study 7820487 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain biopsy (stereotactic and ultrasonographically guided)
Number of subjects: 50
Study 7820487 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain biopsy
Number of subjects: 50
Study 2454980 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional injection of 1 U/ml bleomycin sulfate
Number of subjects: 143
Study 2454980 — intervention group
Group type: COMPARATOR
Intervention: Physiologic saline solution injection (control)
Number of subjects: 143
Study 30354905 — intervention group
Group type: EXPERIMENTAL
Intervention: iRest meditation training
Number of subjects: 30
Study 30354905 — intervention group
Group type: COMPARATOR
Intervention: Vacation control
Number of subjects: 30
Study 27690687 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg daily for 4 weeks, then 1500 mg daily for 8 weeks
Number of subjects: 42
Study 27690687 — intervention group
Group type: COMPARATOR
Intervention: Megestrol 40 mg daily for 12 weeks
Number of subjects: 42
Study 26834024 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigate (NAV)
Number of subjects: 404
Study 26834024 — intervention group
Group type: COMPARATOR
Intervention: Community Care (CC)
Number of subjects: 404
Study 25060103 — intervention group
Group type: EXPERIMENTAL
Intervention: Forgiveness therapy (conducted once a week for 12 weeks)
Number of subjects: 29
Study 25060103 — intervention group
Group type: EXPERIMENTAL
Intervention: Forgiveness therapy
Number of subjects: 29
Study 25060103 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 29
Study 22057729 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized aspirin 500 mg
Number of subjects: 0
Study 22057729 — intervention group
Group type: COMPARATOR
Intervention: Regular aspirin 500 mg tablets
Number of subjects: 0
Study 19150203 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate training in motivational interviewing
Number of subjects: 0
Study 19150203 — intervention group
Group type: COMPARATOR
Intervention: Delayed training
Number of subjects: 0
Study 17181460 — intervention group
Group type: EXPERIMENTAL
Intervention: Cookin' Up Health nutrition intervention
Number of subjects: 262
Study 17181460 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 262
Study 15090480 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training for 8 weeks
Number of subjects: 43
Study 12566892 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (200 mg)
Number of subjects: 13
Study 12566892 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 13
Study 9640412 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (Genotropin) 0.25 IU/Kg/week (0.125 IU/kg/week for the first four weeks)
Number of subjects: 35
Study 9640412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 9404870 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g of creatine monohydrate per day for 5 consecutive days
Number of subjects: 5